Publicacións en colaboración con investigadores/as de Hospital Duran i Reynals (23)

2024

  1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment

2023

  1. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

2022

  1. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 658-669

  2. SEOM—GECOD clinical guideline for unknown primary cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 681-692

2021

  1. Lung Cancer in Spain

    Journal of Thoracic Oncology

  2. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 980-987

2019

  1. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

2018

  1. ARole forCXCR4in peritonealandhematogenous ovarian cancer dissemination

    Molecular Cancer Therapeutics, Vol. 17, Núm. 2, pp. 532-543

2017

  1. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

  2. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

  3. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2016

  1. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1172-1178

  2. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1213-1220

2015

  1. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

2014

  1. Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program

    Expert Opinion on Drug Safety, Vol. 13, Núm. 9, pp. 1165-1173

2012

  1. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours

    Scientific Reports, Vol. 2

2011

  1. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry

    Breast Cancer Research and Treatment, Vol. 128, Núm. 2, pp. 573-579

  2. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

    Clinical Cancer Research, Vol. 17, Núm. 5, pp. 1160-1168

  3. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

    Lung Cancer, Vol. 71, Núm. 2, pp. 191-198

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967